Product image of Maxipulmon (Butamirate Citrate) supplied by GNH India

Maxipulmon

Active Ingredient:
Butamirate Citrate
Origin:
EU

Maxipulmon (Butamirate Citrate)

Butamirate citrate, the active ingredient in Maxipulmon, is an antitussive presented as an oral formulation for oral use. It is employed to relieve dry, non‑productive coughs in adults and children when appropriate, providing symptomatic relief without affecting mucus clearance.

GNH India supplies Maxipulmon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across markets. The company adheres to stringent manufacturing standards and provides reliable logistics support for global distribution.

Manufacturer / TM Owner

Aflofarm Farmacja Polska Sp. Z O.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Maxipulmon, containing butamirate citrate, is used to manage coughs by acting on the cough reflex pathway.

  • Dry cough: reduces frequency and intensity of coughing episodes.
  • Non‑productive cough: provides symptomatic relief in coughs without sputum production.
  • Cough due to upper respiratory tract infections: alleviates irritation‑induced coughing.

How It Works

  • Butamirate citrate suppresses the cough reflex by acting on the cough centre in the medulla oblongata. Although the precise molecular target is not fully defined, the compound modulates neuronal activity that initiates the cough response, leading to a decrease in the urge to cough without significantly impairing normal respiratory function.

Side Effects

Butamirate citrate may cause several adverse reactions, most of which are mild and transient.

Common Side Effects

  • Nausea: mild stomach upset occurring shortly after ingestion.
  • Drowsiness: transient sleepiness, especially at higher doses.
  • Dizziness: brief sensation of light‑headedness.
  • Dry mouth: reduced salivation leading to throat discomfort.
  • Headache: mild to moderate head pain.
  • Gastrointestinal discomfort: mild abdominal cramping or discomfort.

Serious or Rare Side Effects

  • Allergic reactions: rash, itching, swelling, or angioedema requiring medical attention.
  • Hepatic dysfunction: abnormal liver enzyme elevations in rare cases.
  • Severe hypersensitivity: anaphylactic-like reactions demanding urgent care.

Precautions & Warnings

When using Maxipulmon, consider the following safety measures.

  • Pregnancy: consult a healthcare professional; safety has not been established.
  • Breastfeeding: avoid use unless advised by a physician.
  • Asthma or chronic respiratory disease: monitor for any worsening of symptoms.
  • Elderly patients: start with the lowest effective dose and observe for increased sedation.
  • Concomitant CNS depressants: assess for additive drowsiness.
  • Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Butamirate citrate can interact with other medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

  • Monoamine oxidase inhibitors (MAOIs): risk of enhanced central nervous system effects.
  • Strong CNS depressants (e.g., opioids, benzodiazepines): may cause excessive sedation or respiratory depression.

Moderate Interactions (Monitor Closely)

  • Alcohol: can increase drowsiness and impair coordination.
  • Antihistamines: may augment anticholinergic side effects.
  • Selective serotonin reuptake inhibitors (SSRIs): potential for increased serotonergic activity.
  • Other cough suppressants: combined use may lead to over‑suppression of the cough reflex.

Frequently Asked Questions

Maxipulmon contains butamirate citrate, an antitussive that is used to relieve dry and non‑productive coughs. It helps reduce the frequency and intensity of coughing episodes, providing symptomatic comfort for patients with irritation‑induced coughs.

Butamirate citrate acts on the cough centre in the medulla of the brain, suppressing the cough reflex. While the exact molecular target is not fully clarified, the drug modulates neuronal pathways that trigger coughing, thereby decreasing the urge to cough without significantly affecting normal breathing.

The appropriate dose of Maxipulmon is determined by a qualified healthcare professional based on the patient’s age, weight, and clinical condition. Prescribers set the dosage and frequency according to current medical guidelines and individual patient needs.

Safety data for butamirate citrate in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Maxipulmon.

To request Maxipulmon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with opioid‑based antitussives, butamirate citrate offers cough relief without the risk of dependence or significant respiratory depression. It is generally considered milder than codeine‑containing products and is available over‑the‑counter in many EU markets, making it a convenient option for mild to moderate dry coughs.

Store Maxipulmon below 25 °C in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain its stability and effectiveness throughout its shelf life.

Maxipulmon is taken orally, typically as a tablet or liquid preparation, as directed by a healthcare professional. The medication should be swallowed with water and taken at the prescribed intervals, usually after meals to minimize gastrointestinal discomfort.

Serious risks, though rare, include allergic reactions such as rash, swelling or angioedema, and hepatic dysfunction indicated by abnormal liver enzymes. Patients should seek immediate medical attention if they experience signs of a severe hypersensitivity reaction or unexplained liver-related symptoms.

Individuals with known hypersensitivity to butamirate citrate or any excipients in the formulation should avoid Maxipulmon. It is also contraindicated in patients taking monoamine oxidase inhibitors or those with severe respiratory depression without prior medical evaluation.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Butamirate Citrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT